CAR-T cell therapy with stem cell transplant for T-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new treatment that uses your own immune cells, modified to attack cancer cells, followed by a stem cell transplant to help rebuild your immune system. It is for people with a type of T-cell lymphoma that has not responded to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 14 and 65 years old.
- You have a type of T-cell lymphoma (not T-lymphoblastic lymphoma) that is CD7-positive.
- Your lymphoma has not improved after at least one or two standard chemotherapy treatments, or it came back within 12 months after remission.
- You have at least one measurable tumor (e.g., a lymph node larger than 1.5 cm or an extranodal lesion larger than 1 cm).
- You are generally well enough (able to care for yourself, up and about more than half the day) and have adequate organ function (heart, liver, kidneys, lungs).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial combines your own stem cells (collected before) with a special immune cell therapy (CD7-CART) to treat T-cell lymphoma or leukemia. It may help people with high-risk or hard-to-treat disease.
This trial tests a new type of immune cell therapy (called CAR-T) that targets two proteins, CD5 and CD7, on the surface of T-cell leukemia or lymphoma cells. It may be an option for people whose cancer came back or didn't respond to standard treatment.
This study tests a new type of immunotherapy that uses your own immune cells, modified in a lab, to find and attack cancer cells in blood cancers like leukemia, lymphoma, and multiple myeloma. It is for people whose cancer has come back or not responded to standard treatments.
This trial is studying whether a new kind of cellular therapy, called anti-CD7 CAR-T, can help people with relapsed or refractory T-cell lymphoma/leukemia by targeting a specific protein (CD7) on their cancer cells. The treatment uses your own immune cells that are reprogrammed to find and destroy the malignant cells.
This trial studies a type of immune cell therapy (CAR-T) made from your own T-cells, designed to treat T-cell lymphoma or T-cell leukemia that has come back or didn’t respond. It may help by directing your immune system to attack the cancer, and it requires specific eligibility and safety checks.
This trial tests a new treatment using your own immune cells, called CAR-T cells, that are modified to find and attack lymphoma cells with CD20 or CD30 markers. It is for people whose lymphoma has not responded to standard treatments or has returned after treatment.
Hear when a new T-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.